• 2026-03-02 02:28:47

Singapore's Smart Health initiative leverages technology to transform healthcare, addressing an aging population and driving demand for innovative medical devices. As a regional hub with high healthcare spending and import dependency, Singapore offers significant opportunities for med-tech companies focusing on digital health, AI, and assistive technologies. This article will highlight the insights for medical device businesses to leverage Singapore's Smart Health vision.

• 2026-02-26 08:25:34

The Malaysia Medical Device Authority (MDA) has officially gazetted the Medical Device (Designated Medical Device) Order 2026, effective on 1 June 2026. The Order involved medical device primarily used in aesthetic, therapeutic, and clinical settings. To enhance safety and mitigate risks, designated medical devices shall comply with Malaysian regulatory requirement for entering the Malaysian market.

• 2026-02-25 04:43:48

Thai FDA has provided recommendations on applicable international standards for particular types of active medical devices to support medical device registration in Thailand. These standards are presented as advisory references only and are intended to assist the registrants in preparing relevant test reports in accordance with the ASEAN Common Submission Template Dossier (CSDT).

• 2026-02-25 04:14:57

The Ministry of Food and Drug Safety (MFDS) has amended the Regulation on Permission, Notification, Review, Etc. of Medical Devices, effective 26 January 2026. The revision expands acceptable clinical documentation, integrates Class II certification responsibilities, refines the regulatory framework for innovative medical devices, clarifies technical documentation requirements, and strengthens cybersecurity submission obligations for connected devices. These updates aim to enhance regulatory clarity, align with international standards, and improve the efficiency of approval and certification procedures in South Korea.

• 2026-02-25 03:48:52

PMDA recently released the revision for managing changes to raw materials used in medical devices. The revision clarifies the scope of minor change notifications that do not impact safety or performance and consolidates the criteria for determining applicability in low-risk cases or where sufficient prior usage experience exists.

• 2026-01-30 07:13:08

Thailand has updated its medical device labeling and IFU regulation, which will take effect on June 20, 2026. The new regulations expand the scope to include Software as Medical Device (SaMD), reusable surgical and dental instruments, and medical device accessories. Manufacturers and Importers are granted transition period until June 20, 2028, to transition from the 2020 requirements to the new 2025 requirements. Medical device companies marketing products in Thailand must update their labeling and IFU to comply with this updated announcement by the enforcement deadline.

• 2026-01-30 04:29:37

The European Union has established post-market surveillance (PMS) requirements under the Medical Device Regulation (MDR) and In Vitro Diagnostic Medical Device Regulation (IVDR) to ensure the continuous safety and performance of medical devices and IVDs placed on the market. This framework emphasizes proactive monitoring, data collection, and lifecycle-based compliance to promptly identify and address potential risks.

• 2026-01-30 04:16:17

NMPA released the 2025 Catalog of High-End Medical Devices for Priority Approval to expedite the registration process for innovative high-end medical devices.

• 2026-01-30 03:45:43

The NMPA issued revised regulation on the administration of export sales certificates of medical devices, effective May 1, 2026.

• 2025-12-26 04:30:43

The Indonesian medical aesthetics market is projected to grow significantly, reaching is it USD 450.23 million by 2028, driven by increasing awareness and demand for cosmetic procedures. Key market drivers include advanced cosmetic technologies, a growing middle-class population, and supportive government policies. However, challenges such as regulatory constraints and high procedural costs remain.